See more : Premier Miton Group plc (PASMF) Income Statement Analysis – Financial Results
Complete financial analysis of Aerovate Therapeutics, Inc. (AVTE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aerovate Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kadem Sustainable Impact Corporation (KSICW) Income Statement Analysis – Financial Results
- M3 Mining Limited (M3M.AX) Income Statement Analysis – Financial Results
- GrandSouth Bancorporation (GRRB) Income Statement Analysis – Financial Results
- Astera Labs, Inc. Common Stock (ALAB) Income Statement Analysis – Financial Results
- Universal Health Services, Inc. (UHS) Income Statement Analysis – Financial Results
Aerovate Therapeutics, Inc. (AVTE)
About Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 96.00K | 68.00K | 15.00K | 1.00K | 0.00 |
| Gross Profit | -96.00K | -68.00K | -15.00K | -1.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 64.22M | 38.62M | 14.99M | 7.94M | 3.11M |
| General & Administrative | 17.19M | 14.62M | 8.04M | 949.00K | 218.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.19M | 14.62M | 8.04M | 949.00K | 218.00K |
| Other Expenses | 0.00 | -79.00K | -3.00K | -647.00K | 1.00K |
| Operating Expenses | 81.41M | 53.24M | 23.02M | 8.89M | 3.33M |
| Cost & Expenses | 81.41M | 53.24M | 23.02M | 8.89M | 3.33M |
| Interest Income | 5.95M | 1.83M | 65.00K | 75.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 65.00K | 75.00K | 0.00 |
| Depreciation & Amortization | 96.00K | 68.00K | 15.00K | 1.00K | 3.33M |
| EBITDA | -81.31M | -53.17M | -23.01M | -8.89M | 1.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -81.41M | -53.24M | -23.02M | -8.89M | -3.33M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.94M | 1.75M | 62.00K | -722.00K | 2.00K |
| Income Before Tax | -75.47M | -51.49M | -22.96M | -9.61M | -3.33M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 56.00K | 25.00K | 3.00K | -572.00K | 1.00K |
| Net Income | -75.52M | -51.51M | -22.96M | -9.04M | -3.33M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.87 | -2.10 | -0.94 | -0.37 | -0.14 |
| EPS Diluted | -2.87 | -2.10 | -0.94 | -0.37 | -0.14 |
| Weighted Avg Shares Out | 26.33M | 24.47M | 24.41M | 24.41M | 24.41M |
| Weighted Avg Shares Out (Dil) | 26.33M | 24.47M | 24.41M | 24.41M | 24.41M |
INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. – AVTE
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. - AVTE
NEW YORK , Nov. 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders
NEW YORK , Nov. 1, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Aerovate Therapeutics,...
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aerovate Therapeutics, Inc. (NASDAQ: AVTE) and Jade Biosciences is fair to Aerovate shareholders. Upon closing of the proposed transaction, Aerovate stockholders are expected to...
Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Aerovate (Nasdaq: AVTE) for possible breaches of fiduciary duty and other violations of law in its transaction with Jade. Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995....
Aerovate Therapeutics to Explore Strategic Alternatives
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as...
The 3 Hottest Stock Downgrades From Last Week
Wall Street's leading analysts have been adjusting their S&P 500 forecasts in recent days. Driven by potential Federal Reserve interest rate cuts, strong performance from large technology companies and solid corporate earnings growth, analysts expect the S&P 500 to consolidate...
Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC
ATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (NASDAQ: AVTE) complied with federal securities laws. On June 17, 2024, Aerovate announced topline results from the Phase 2b portion...
Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.
Source: https://incomestatements.info
Category: Stock Reports